Literature DB >> 10493335

Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies.

T Nieminen1, H Käyhty, O Leroy, J Eskola.   

Abstract

BACKGROUND: Our previous studies have shown an antibody-secreting cell (ASC) response to pneumococcal vaccines in adults and suggested that a high IgA ASC response is an indicator of a secretory IgA response in saliva. We believe that the mucosal immune response is potentially an important characteristic of the pneumococcal vaccines and should thus be measured when the new pneumococcal conjugate vaccines are evaluated.
OBJECTIVES: To study mucosal and serum antibody responses to pneumococcal conjugate vaccines in toddlers.
METHODS: Each investigational vaccine, containing either 3 or 10 microg of pneumococcal PS serotypes 6B, 14, 19F and 23F conjugated to either diphtheria toxoid (PncD) or tetanus protein (PncT), was administered to 10 children (a total of 40 children). The ASC response was measured on Day 7 after immunization by enzyme-linked immunospot assay, and the salivary and serum antibodies were measured before and 7 and 28 days after the immunization by enzyme immunoassay.
RESULTS: The vaccines studied induced ASC responses to the pneumococcal polysaccharides (PS) in all children vaccinated. The ASC responses to the PS components of the vaccine (the geometric mean number of ASCs varying from 120 to 160 ASC/10(6) cells) were lower than those seen earlier in adults after conjugate vaccine (240 to 2015 ASC/10(6) cells), but comparable with those seen earlier in adults after pneumococcal PS vaccine (113 to 136 ASC/10(6) cells). The ASC response was clearly dominated by IgA-secreting cells. Salivary IgA responses were detected in 35% of the children, but IgG was rarely detected in saliva. A positive correlation was demonstrated between the number of IgA ASCs and salivary IgA concentration (r = 0.70, P = 0.01), suggesting that a high number of IgA ASCs after parenteral immunization is an indicator of a secretory IgA response in saliva. On Day 28 after immunization increased serum concentrations of IgG were detected in most vaccinees (75 to 95%, depending on the serotype).
CONCLUSIONS: Both mucosal and systemic antibody responses were induced by PncD and PncT vaccines in toddlers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493335     DOI: 10.1097/00006454-199909000-00005

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  10 in total

1.  Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure.

Authors:  J McVernon; P D R Johnson; A J Pollard; M P E Slack; E R Moxon
Journal:  Arch Dis Child       Date:  2003-05       Impact factor: 3.791

2.  Association of serotype-specific antibody concentrations and functional antibody titers with subsequent pneumococcal carriage in toddlers immunized with a 9-valent pneumococcal conjugate vaccine.

Authors:  Birgit Simell; Anu Nurkka; Mika Lahdenkari; Noga Givon-Lavi; Helena Käyhty; Ron Dagan; Jukka Jokinen
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

Review 3.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

4.  Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.

Authors:  Birgit Simell; Anu Nurkka; Nina Ekström; Noga Givon-Lavi; Helena Käyhty; Ron Dagan
Journal:  Clin Vaccine Immunol       Date:  2012-08-08

5.  Comparison of a classical phagocytosis assay and a flow cytometry assay for assessment of the phagocytic capacity of sera from adults vaccinated with a pneumococcal conjugate vaccine.

Authors:  W T Jansen; M Väkeväinen-Anttila; H Käyhty; M Nahm; N Bakker; J Verhoef; H Snippe; A F Verheul
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

Review 6.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

7.  Pneumococcal carriage in children in The Netherlands: a molecular epidemiological study.

Authors:  D Bogaert; M N Engelen; A J Timmers-Reker; K P Elzenaar; P G Peerbooms; R A Coutinho; R de Groot; P W Hermans
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

Review 8.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Salivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial.

Authors:  Anu Nurkka; Mika Lahdenkari; Arto A I Palmu; Helena Käyhty
Journal:  BMC Infect Dis       Date:  2005-05-27       Impact factor: 3.090

Review 10.  Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining?

Authors:  Stephen K Obaro; Shabir A Madhi
Journal:  Lancet Infect Dis       Date:  2006-03       Impact factor: 25.071

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.